An overarching area of research in Memorial Sloan-Kettering's Plastic and Reconstructive Surgical Service is measuring patients' quality of life after reconstruction.
Memorial Sloan-Kettering's new breast center will offer patients the most advanced outpatient services for the diagnosis and treatment of breast cancer, as well as leading-edge diagnostic and treatment-planning services for many types of cancer.
Three young investigators who have taken significant steps toward advancing the understanding of cancer were recipients of the 2009 Paul Marks Prize for Cancer Research, a prize awarded biennially by Memorial Sloan-Kettering since 2001 to scientists under the age of 46.
Memorial Sloan-Kettering's Gerstner Sloan-Kettering Graduate School of Biomedical Sciences was recently named one of 23 research institutions to receive a grant from the Howard Hughes Medical Institute as part of their Med into Grad Initiative.
For some women, an unfortunate consequence of breast cancer surgery can be a condition called lymphedema, an accumulation of lymphatic fluid that causes an abnormal swelling of an extremity. While there is currently no good treatment or prevention method for lymphedema, researchers at Memorial Sloan-Kettering are working to try and understand the etiology of this condition, which affects 90 million to 150 million people worldwide each year.
A new study by researchers at Memorial Sloan-Kettering shows that circulating tumor cells -- cancer cells that break away from a primary tumor and disseminate to other areas of the body -- can also return to and grow in their tumor of origin, a newly discovered process called "self-seeding."
The National Cancer Institute has awarded several institutions, including Memorial Sloan-Kettering, a grant to help better understand the physical laws and principles that shape and govern the emergence and behavior of cancer.
Research and testing conducted at Memorial Sloan-Kettering has yielded a new drug to help fight peripheral T cell lymphoma, a rare but aggressive form of cancer that most often becomes resistant to standard chemotherapy.
Memorial Sloan-Kettering investigators have shown that a new type of cancer vaccine might be more effective than previous therapies at inducing immune cells to destroy tumors.
In a recently published Nature study, Memorial Sloan-Kettering researchers engineered stem cells from patients with familial dysautonomia (FD), a rare genetic disorder, and used them to explore the causes of the disease and to test drugs that might be effective against it. The study shows how a human disease can be modeled in a tissue culture dish -- a concept with wide applications for research and drug development.
A new study from researchers at Memorial Sloan-Kettering has found that the majority of surgeons treating prostate cancer in the United States have extremely low annual caseloads, potentially leading to increased rates of both surgical complications and cancer recurrence.
News@MSKCC provides journalists with news and information from Memorial Sloan-Kettering Cancer Center and is released six times a year.
For more information about these and other potential story ideas, contact Memorial Sloan-Kettering's Department of Public Affairs at: 212-639-3573 or at mediastaff@mskcc.org
